CoAprovel 300mg/12.5mg Tablet

Manufacturer
SANOFI WINTHROP INDUSTRIE
 
Contents
Per 300/12.5tab Irbesartan 300 mg, hydrochlorothiazide 12.5 mg. 
 
Indication
HTN. May be used either alone or in combination w/ other antihypertensive agents (eg, β-adrenergic blocking agent, long-acting Ca channel blocking agent). As initial therapy in patients who are likely to need multiple drugs to achieve their BP goals.
 
Instruction
May be taken with or without food.
 
Drug interaction
Increased serum conc, decreased renal clearance, & increased toxicity of lithium. Irbesartan: Attenuation of antihypertensive effects, & deterioration of renal function including possible acute renal failure w/ NSAIDs including selective COX-2 inhibitors. Hydrochlorothiazide: Potentiation of thiazide diuretic-induced orthostatic hypotension w/ alcohol, barbiturates or narcotics. May elevate blood glucose, uric acid & serum Ca levels; adjust dose of antidiabetics including oral agents & insulin, antigout medication, & Ca or Ca-sparing drugs, respectively, when used concomitantly w/ hydrochlorothiazide. Delayed absorption w/ cholestyramine resin & colestipol HCl. Decreased effect w/ endogenous prostaglandin synthesis inhibitors ie, NSAIDs. Potentiates actions of other antihypertensives especially ganglion- or peripheral adrenergic-blocking drugs. May interact w/ diazoxide. Potentiates effects of non-depolarizing muscle relaxants, pre-anesth & anesth eg, tubocurarine; reduce dose of pre-anesth & anesth, & if possible discontinue hydrochlorothiazide 1 wk prior to surgery. Risk of symptomatic hyponatremia w/ carbamazepine.